Pathophysiology of β2-glycoprotein i in antiphospholipid syndrome

E. Matsuura, L. Shen, Y. Matsunami, N. Quan, M. Makarova, F. J. Geske, M. Boisen, S. Yasuda, K. Kobayashi, L. R. Lopez

Research output: Contribution to journalReview articlepeer-review

27 Citations (Scopus)


Since β2-glycoprotein I (β2GPI) was described as the major antigenic target for antiphospholipid antibodies, many studies have focused their attention to the physiological role of β2GPI and anti-β2GPI antibodies on autoimmune-mediated thrombosis. Studies reporting the physiological role of β2GPI have been numerous, but the exact mechanism of action(s) has yet to be completely determined. β2GPIs epitopes for anti-β2GPI autoantibodies have been characterized, however, not all of the heterogeneous anti-β2GPI antibodies are pathogenic. The pathophysiologic role of β2GPI has been reported in the fields of coagulation, fibrinolysis, angiogenesis, and atherosclerosis. Our understanding of the impact of β2GPI, its metabolites and autoantibodies to β2GPI on these physiological functions may contribute to the development of better therapeutic strategies to treat and prevent autoimmune-mediated atherothrombotic vascular disease.

Original languageEnglish
Pages (from-to)379-384
Number of pages6
Issue number4
Publication statusPublished - Apr 2010
Externally publishedYes


  • Angiogenesis
  • Atherosclerosis
  • Pro-coagulation
  • β2-glycoprotein I fibrinolysis

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Pathophysiology of β2-glycoprotein i in antiphospholipid syndrome'. Together they form a unique fingerprint.

Cite this